Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
long-acting glucagon receptor agonist
- Development stage
- Preclinical
- Lead developer
- i2o Therapeutics
- Modality
- Peptides
- Administration
- Oral, Implant
01
Overview
Long-Acting Glucagon RA is a therapeutic candidate under development by i2o Therapeutics, targeting the glucagon receptor (GCGR) for the treatment of obesity and cardio-renal-metabolic diseases. As a long-acting receptor agonist, it is designed to provide sustained activation of glucagon signaling, which plays a critical role in regulating glucose homeostasis, increasing energy expenditure, and promoting weight loss. The program is part of i2o Therapeutics' pipeline, which focuses on leveraging proprietary technology—such as ionic liquid formulations—to improve the delivery and efficacy of biologic therapies. While i2o Therapeutics is primarily known for its oral delivery platform, this specific program is characterized in the pipeline as a long-acting agonist aimed at addressing the complex needs of patients with metabolic and cardiovascular conditions.
- Other names
- Long-Acting Glucagon RALong-Acting Glucagon Receptor Agonist
02
Targets
GCGR (Glucagon receptor)
Beyond the preview
Go deeper on long-acting glucagon receptor agonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on long-acting glucagon receptor agonist.